Literature DB >> 25911904

Glycemic changes after gastrectomy in non-morbidly obese patients with gastric cancer and diabetes.

Zhiyong Shen, Jiang Yu, Shangtong Lei, Tingyu Mou, Yanfeng Hu, Hao Liu, Guoxin Li.   

Abstract

BACKGROUND/AIMS: To evaluate the glycemic changes after gastrectomy in non-morbidly obese patients with gastric cancer (GC) and type 2 diabetes mellitus (T2DM).
METHODOLOGY: Between December 2011 and June 2014, we included 46 patients with gastric cancer and T2DM of a body mass index (BMI) < 30 kg/m2, who underwent gastrectomy in our center. The comparisons of FPGs in specific periods were performed according to age, extent of gastrectomy, reconstruction type, preoperative triglyceride (TG) level and so on.
RESULTS: The non-morbidly obese patients experienced an improvement of glycemic control. T2DM resolution happened 3 weeks after surgery. FPG decreased significantly after postoperative day 21 compared to preoperative FPG. 32 patients experienced DM improvement after postoperative day 21. The age and relatively lower preoperative TG patients, who underwent total gastrectomy (P<0.001) or duodenal bypass reconstruction (Billroth II, Roux-en-Y gastrojejunostomy, or Roux-en-Y esophagojejunostomy, P=0.009) appeared to have a better glycemic control.
CONCLUSIONS: Our finding observed through this simulation model suggested that non-morbidly obese patients may also benefit from metabolic surgery for glycemic control, associated with age, extent of gastrectomy, reconstruction type, and preoperative triglyceride level.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25911904

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  3 in total

1.  Angiogenesis and inflammation at the crossroads between diabetes and cancer: PS226.

Authors:  R Rocha; I Rodrigues; I Gullo; G Gonçalves; J Pedro; D Carvalho; F Carneiro; R Soares; S Andrade
Journal:  Porto Biomed J       Date:  2017-09-01

Review 2.  Gastrointestinal dopamine as an anti-incretin and its possible role in bypass surgery as therapy for type 2 diabetes with associated obesity.

Authors:  Suleman Chaudhry; Marilia Bernardes; Paul E Harris; Antonella Maffei
Journal:  Minerva Endocrinol       Date:  2015-10-27       Impact factor: 2.184

3.  A randomized controlled trial of Roux-en-Y gastrojejunostomy vs. gastroduodenostomy with respect to the improvement of type 2 diabetes mellitus after distal gastrectomy in gastric cancer patients.

Authors:  Yoon Young Choi; Sung Hoon Noh; Ji Yeong An
Journal:  PLoS One       Date:  2017-12-07       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.